gptkbp:instanceOf
|
gptkb:drug
dissociative anesthetic
|
gptkbp:ATCCode
|
gptkb:N01AX03
|
gptkbp:black_box_warning
|
no
|
gptkbp:can_cause_bladder_toxicity
|
yes
|
gptkbp:can_cause_cognitive_impairment
|
yes
|
gptkbp:can_cause_dependence
|
yes
|
gptkbp:CASNumber
|
6740-88-1
|
gptkbp:chemicalFormula
|
C13H16ClNO
|
gptkbp:discoveredBy
|
gptkb:Calvin_Stevens
|
gptkbp:discoveredIn
|
1962
|
gptkbp:eliminationHalfLife
|
2.5–3 hours
|
gptkbp:excretion
|
gptkb:kidney
|
gptkbp:first_approved_for_medical_use
|
1970
|
gptkbp:has_antidepressant_effect
|
yes
|
gptkbp:has_rapid_onset_of_action
|
yes
|
gptkbp:hasEnantiomer
|
gptkb:arketamine
gptkb:esketamine
|
gptkbp:hasStreet
|
gptkb:Kit_Kat
gptkb:Special_K
K
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ketamine
|
gptkbp:IUPACName
|
(RS)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
|
gptkbp:KEGGID
|
D08014
|
gptkbp:legalStatus
|
gptkb:Class_B_(UK)
gptkb:Schedule_III_(US)
Schedule I (Canada)
|
gptkbp:mechanismOfAction
|
NMDA receptor antagonist
dopamine reuptake inhibitor
opioid receptor agonist (weak)
|
gptkbp:meltingPoint
|
258–261 °C (hydrochloride salt)
|
gptkbp:MeSH_ID
|
D007662
|
gptkbp:metabolism
|
liver
|
gptkbp:molecularWeight
|
237.725 g/mol
|
gptkbp:overdoseSymptoms
|
coma
seizures
respiratory depression
|
gptkbp:pregnancyCategory
|
C (US)
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL402
3821
DB01221
|
gptkbp:relatedTo
|
gptkb:methoxetamine
gptkb:phencyclidine
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
intranasal
|
gptkbp:sideEffect
|
nausea
dissociation
hallucinations
agitation
elevated blood pressure
|
gptkbp:solubility
|
soluble in water (hydrochloride salt)
|
gptkbp:UNII
|
690G0D6V8H
|
gptkbp:used_in_veterinary_medicine
|
yes
|
gptkbp:used_recreationally
|
yes
|
gptkbp:usedFor
|
pain management
treatment-resistant depression
anesthesia
status epilepticus
sedation
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
gptkbp:bfsParent
|
gptkb:Schedule_III
gptkb:Princess_Goes_to_the_Butterfly_Museum
|
gptkbp:bfsLayer
|
6
|